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Polycomb-like proteins 1–3 (PCL1–3) are substoichiometric components of the Polycomb-repressive complex 2
(PRC2) that are essential for association of the complex with chromatin. However, it remains unclear why three
proteins with such apparent functional redundancy exist in mammals. Here we characterize their divergent roles in
both positively and negatively regulating cellular proliferation. We show that while PCL2 and PCL3 are E2F-regu-
lated genes expressed in proliferating cells, PCL1 is a p53 target gene predominantly expressed in quiescent cells.
Ectopic expression of any PCL protein recruits PRC2 to repress the INK4A gene; however, only PCL2 and PCL3
confer an INK4A-dependent proliferative advantage. Remarkably, PCL1 has evolved a PRC2- and chromatin-inde-
pendent function to negatively regulate proliferation. We show that PCL1 binds to and stabilizes p53 to induce
cellular quiescence. Moreover, depletion of PCL1 phenocopies the defects in maintaining cellular quiescence as-
sociated with p53 loss. This newly evolved function is achieved by the binding of the PCL1N-terminal PHD domain
to the C-terminal domain of p53 through two unique serine residues, which were acquired during recent vertebrate
evolution. This study illustrates the functional bifurcation of PCL proteins, which act in both a chromatin-depen-
dent and a chromatin-independent manner to regulate the INK4A and p53 pathways.
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Polycomb group proteins are chromatin-associated gene
repressorswith essential roles in embryonic development,
stem cell differentiation, and cellular proliferation (Sauva-
geau and Sauvageau 2010; Lanzuolo and Orlando 2012).
They were identified in Drosophila melanogaster based
on their requirement for maintaining the repressed state
of homeotic genes during embryonic development (Di
Croce and Helin 2013). Subsequent genome-wide binding
studies in both D. melanogaster and mammalian cells
confirmed that Polycombs directly bind homeotic gene
loci in addition to a broader cohort of developmental
genes (Boyer et al. 2006; Bracken 2006; Lee et al. 2006;
Tolhuis et al. 2006). Polycombs form multiprotein com-
plexes, the best characterized of which are Polycomb-
repressive complex 1 (PRC1) and PRC2 (Simon and
Kingston 2013). The PRC1 complex is defined by a heter-
odimeric RING-PCGF core that mediates the monoubi-
quitination of histone H2A at Lys119 (Gao et al. 2012;
Tavares et al. 2012), while the PRC2 complex is composed
of a trimeric core of SUZ12, EED, and EZH1/2 and meth-
ylates histoneH3 at Lys27 (Margueron andReinberg 2011;
Ferrari et al. 2014). Recent genetic evidence indicates that
the function of the PRC2 complex is deregulated in mul-
tiple cancer types (Hock 2012; Helin and Dhanak 2013).
However, it is unclear whether PRC2 deregulation con-
tributes to cancer progression by disrupting stem cell dif-
ferentiation, cellular proliferation, or both.
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PRC1 and PRC2 have a well-established role in the reg-
ulation of cellular proliferation via their ability to confer
chromatin-mediated repression of the INK4A gene locus
(Jacobs et al. 1999; Lessard and Sauvageau 2003; Park
et al. 2003; Gil et al. 2004; Bracken et al. 2007; Maertens
et al. 2009). The INK4A gene encodes the p16 protein,
a cyclin-dependent kinase (CDK) inhibitor and key up-
stream regulator of cellular senescence (Collado et al.
2007; Lanigan et al. 2011). The ectopic expression of the
PRC1 complex components BMI1 (Jacobs et al. 1999;
Bracken et al. 2007), CBX7 (Gil et al. 2004), CBX8 (Die-
trich et al. 2007), and KDM2B (Tzatsos et al. 2009) confers
a proliferative advantage to primary cells due to sustained
repression of INK4A. Accordingly, deletion of Bmi1, Eed,
or Ezh1 results in derepression of Ink4a and consequent
stem and progenitor cell senescence (Lessard and Sauva-
geau 2003; Molofsky et al. 2003; Park et al. 2003; Hidalgo
et al. 2012; Xie et al. 2014). However, it is also clear that
Polycombs can regulate cellular proliferation indepen-
dently of INK4A repression (Bruggeman et al. 2007; Datta
et al. 2007; Douglas et al. 2008; Piunti et al. 2014).
Polycombs have emerging, albeit less well-character-
ized, roles in the control of cellular proliferation in-
dependent of chromatin association. For example, in
D. melanogaster, the mammalian PCGF homolog Psc
ubiquitinates the mitotic regulator Cyclin-B, thereby me-
diating its proteasomal degradation (Mohd-Sarip et al.
2012). This interaction is essential for normal cell cycle
progression, as loss of Psc leads to an accumulation of cells
undergoing abnormalmitoses. Inmammals, the PCGF1–6
proteins have not been ascribed a similar chromatin-inde-
pendent role, likely because they lack the extended C-ter-
minal region of Psc needed to interact with Cyclin-B.
Interestingly, the mammalian SCML2 gene encodes two
isoforms: the chromatin- and PRC1-associated SCML2A
and the predominantly nucleoplasmic SCML2B. SCML2B
associates with CDK/CYCLIN/p21 and p27 complexes to
enhance the function of p21/p27, thereby reducing pro-
gression through the cell cycle (Lecona et al. 2013). These
observations indicate that Polycombs may play a broad
role in cellular proliferation control beyond their canoni-
cal function as chromatin-associated gene repressors.
However, currently, no component of the PRC2 complex
has been linked with a chromatin-independent role in the
control of cellular proliferation.
The Polycomb-like (PCL) proteins PCL1–3 (also known
as PHF1,MTF2, and PHF19, respectively) are substoichio-
metric PRC2 complex components that are required for
the maintenance and de novo recruitment of PRC2
to chromatin (Ballaré et al. 2012; Brien et al. 2012; Di
Croce and Helin 2013). We and others demonstrated
that the Tudor domains of PCL1–3 bind to H3K27me3
andH3K36me2/3 in vitro and are essential for themainte-
nance of PRC2 on chromatin in embryonic stem cells
and its recruitment to de novo sites during differentia-
tion (Ballaré et al. 2012; Brien et al. 2012; Musselman
et al. 2012; Cai et al. 2013). However, despite being indis-
pensible for PRC2 function, the potential roles of PCL
proteins in the control of cellular proliferation have yet
to be addressed.
Here we demonstrate the functional bifurcation of
PCL1–3 in regulating cellular proliferation. First, we
show that while PCL2 and PCL3 are transcriptionally
regulated by the E2F pathway, PCL1 is a direct target
gene of p53 and is highly expressed in noncycling, quies-
cent cells. While all three PCL proteins recruit PRC2
to directly repress INK4A, only PCL2 and PCL3 confer
an INK4A-dependent proliferative advantage. In contrast
to PCL2 and PCL3, we show that PCL1 has an INK4A-,
PRC2-, and chromatin-independent role in mediating a
p53-dependent growth arrest. We also show that the N-
terminal PHD domain of PCL1 has diverged functionally
from that of PCL2 and PCL3 by using two unique serine
residues to physically interact with the p53 C-terminal
domain (CTD). As reported previously, the interaction of
PCL1 with p53 leads to stabilization of p53 protein levels
and increased expression of p53 target genes (Yang et al.
2013); however, we further show that this increase in
p53 levels is associated with induction of cellular quies-
cence. Conversely, depletion of PCL1 in quiescent cells
phenocopies p53 loss, leading to a failure to maintain cel-
lular quiescence. Taken together, these data reveal that,
while all three PCL proteins regulate the INK4A pathway
via a chromatin-dependentmechanism, PCL1 has evolved
a PRC2- and chromatin-independent role in the regulation
of the p53 pathway and cellular quiescence.
Results
PCL gene expression is divergently regulated in cycling
and noncycling cells
To begin to understand why three PCL genes exist in
mammals, we examined the mRNA expression of all
three genes in FACS-purified populations from the mouse
hematopoietic system (Fig. 1A,B). This demonstrated that
Pcl1 is most highly expressed in quiescent (noncycling)
long-term hematopoietic stem cells (LT-HSCs), while its
expression is sharply reduced in the proliferating common
myeloid progenitor (CMP) and granulocyte macrophage
progenitor (GMP) populations (Fig. 1B). Conversely, Pcl2
and Pcl3 are both expressed at low levels in LT-HSCs
and are induced in the proliferating progenitor popula-
tions. Importantly, the proliferative status and identity
of these sorted cells were confirmed by analyzing the ex-
pression of the cell cycle regulators Cdkn1a and Ccna2
and the HSC marker Meis1 (Fig. 1B). Next, we sought to
ascertain whether the expression of human PCL1–3 is
similarly associated with cellular proliferation. To do
this, wemonitored the expression of PCL1–3 in asynchro-
nously growing and quiescent human diploid fibroblasts
(HDFs). HDFs were serum-starved for 96 h, resulting in
cell cycle exit, as evidenced by the absence of Cyclin A2
protein and increased CDKN1A mRNA levels (Fig. 1C,
D). Quantitative RT–PCR andWestern blot analyses dem-
onstrated that PCL1, but not PCL2/3, is present at both
the mRNA and protein level in quiescent cells. Stimula-
tion of quiescent HDFs to re-enter the cell cycle led to in-
creases in the mRNA and protein levels of PCL2/3 and
decreases in the mRNA levels of PCL1 and CDKN1A,
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accompanied by a decrease in the protein levels of p53 pro-
tein (Fig. 1C,D). Taken together, these data indicate that
the mammalian PCL proteins are divergently expressed
in cycling and noncycling cells.
Next, transcription factor-binding motif analysis iden-
tified consensus E2F-binding sites in the PCL2 and
PCL3 gene promoters and a motif with a high degree of
similarity to the consensus p53-binding site in the PCL1
promoter, which could potentially explain their divergent
transcriptional regulation (Fig. 1E). Chromatin immuno-
precipitation (ChIP) analyses for E2F factors and p53 in
quiescent and cycling HDFs demonstrated that the pro-
moters of PCL2 and PCL3 were strongly bound by E2F1
(an activating E2F transcription factor) in cycling HDFs
and E2F4 (a repressive E2F) in quiescent HDFs (Fig. 1F;
Supplemental Fig. S1), comparable with EZH2, which
we previously reported as an E2F-regulated gene (Bracken
et al. 2003). In contrast, the PCL1 promoter was bound by
p53 in quiescent HDFs, albeit to a lesser extent than the
CDKN1A promoter, which contains a perfect consensus
p53-binding site. Taken together, these data demonstrate
that the divergent expression of PCL1, compared with
PCL2–3 in primary cells, is regulated by the p53 and E2F
pathways, respectively.
PCL proteins execute divergent roles in cellular
proliferation control
To investigate the potential divergent roles of PCL
proteins in cell growth control, we ectopically expressed
all three proteins in HDFs. Interestingly, while ectopic
expression of PCL2 and PCL3 promoted cellular prolifera-
tion and delayed the onset of cellular senescence, ectopic
expression of PCL1 did not (Supplemental Fig. S2; data not
shown). In order to ascertainwhether the observed growth
advantage in PCL2- and PCL3-expressing cells was depen-
dent on p16INK4A, we ectopically expressed PCL1–3 in
HDFs expressing either scrambled (shSCR)-specific or
INK4A-specific (shINK4A) shRNAs (Fig. 2A). This dem-
onstrated that the growth advantage conferred by PCL2/3
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Figure 1. PCL1 is a p53 target gene highly
expressed in quiescent cells. (A) Schematic
representation of the mouse hematopoietic
differentiation hierarchy. Asterisks indi-
cate the largely quiescent long-term and
short-term HSC (LT/ST-HSC) populations
and the highly proliferative CMP and
GMP cell populations. (B) Quantitative
RT–PCR analyses of the indicated mRNA
transcripts in the highlighted (∗) in vivo
FACS-purified populations. (C ) Quantita-
tive RT–PCR analyses of the indicated
mRNA transcripts in asynchronously (AS)
growing HDFs or the same cells following
96 h of serum starvation (quiescent [Q]).
Starved cells were further induced to re-en-
ter the cell cycle following addition of 20%
serum for the indicated time points up to
24 h. (D) Western blot analyses using the
indicated antibodies on whole-cell protein
lysates from the cells in C. (E) Schematic
representations of the PCL1, PCL2, and
PCL3 promoters indicating the presence
of a p53 consensus binding site in the
PCL1 promoter and consensus E2F-binding
sites in the PCL2 and PCL3 promoters.
The Jaspar program (Sandelin et al. 2004)
identified consensus E2F sites in the
PCL2 and PCL3 promoters but not in the
PCL1 promoter. The TRANSFAC program
(Matys et al. 2006) identified a consensus
p53 site in the PCL1 promoter but not in
the PCL2 or PCL3 promoters. (F ) Quan-
titative chromatin immunoprecipitation
(ChIP) analyses using the indicated anti-
bodies in HDFs following 96 h of serum
starvation (quiescent [Q]) or the same cells
following treatment with 20% serum for
24 h (C). Precipitated DNA was analyzed
by quantitative PCR using primers directed
toward the promoters of the indicated
genes. ChIP enrichments are presented as the percentage of protein bound normalized to input. The data represent the average of three
biological replicates.
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was completely dependent on p16INK4A (Fig. 2B). Striking-
ly, ectopic expression of PCL1 in shINK4A HDFs led to a
significant reduction in the rate of cellular proliferation
(Fig. 2B), which was associated with an increased
proportion of cells in G0/G1 phase of the cell cycle (Fig.
2C). This suggests that PCL1 plays a role independent
of INK4A to negatively affect cellular proliferation. De-
spite this difference, the ectopic expression of all three
PCL proteins led to repression of p16INK4A (Fig. 2D), and
ChIP analyses demonstrated that all three proteins local-
ized to the INK4A gene promoter, which correlated
with recruitment of EZH2 and increased levels of
H3K27me3 (Fig. 2E). Taken together, these data suggest
that while all three PCL proteins recruit PRC2 to repress
INK4A, PCL1 has a divergent role in the control of cellular
proliferation.
PCL1 specifically binds and stabilizes p53 to block
cellular proliferation
Wenext sought to explore themechanism bywhich PCL1
confers its specific, negative effect on cellular prolifera-
tion. A recent study established that PCL1 interacts
with and stabilizes p53 by blocking MDM2-mediated
ubiquitination (Hong et al. 2008; Yang et al. 2013). To
determine whether this interaction is specific to PCL1
and not PCL2 and PCL3, we performed endogenous
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Figure 2. An anti-proliferative role for PCL1 independent of INK4A. (A) Western blot analyses using the indicated antibodies of whole-
cell protein lysates prepared fromHDFs infected with the indicated pBABE retrovirus at population doubling 32 (PD32), where cells were
previously infected with either control (shSCR) or INK4A targeting (shINK4A) pLKO lentivirus at PD28. Westerns were performed at
PD48. (B) 3T3 growth assays performed on cells fromA. Assays were initiated at PD36 and continued for 72 d or until the control shSCR
cells became senescent. (C ) Quantitative cell cycle BrdU FACS analyses of cells from B, performed at day 48 of the 3T3 assay. Analyses
were performed on two independent biological replicates. (D) Quantitative RT–PCR analysis of the INK4A mRNA in cells from C. (E)
Quantitative ChIP analyses using the indicated antibodies on cells from C. ChIPs were performed at PD48. Precipitated DNA was ana-
lyzed by quantitative PCR using primers directed toward the promoters of the indicated genes. ChIP enrichments are presented as the
percentage of protein bound normalized to input.
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coimmunoprecipitations (co-IPs) of p53 and PCL1–3 in
HDFs (Fig. 3A), which demonstrated that PCL1 is the
only PCL capable of coimmunoprecipitating p53. More-
over, in the reciprocal co-IP, PCL1 was the only PCL
that coimmunoprecipitated with p53. Interestingly, the
PCL1–p53 interaction is independent of the PRC2 com-
plex and MDM2, as p53 did not copurify any other
PRC2 components (Fig. 3A; Supplemental Fig. S3A), and
MDM2 does not immunoprecipitate PCL1.
We next examined whether the ability of PCL1 to neg-
atively affect cellular proliferation is dependent on p53.
To do this, we ectopically expressed PCL1–3 in HDFs ex-
pressing either a scrambled control shRNA (shSCR) or a
TP53-specific (shTP53) shRNA (Fig. 3B). Strikingly, 3T3
growth assays and BrdU FACS analyses of these cells re-
vealed that, in the absence of p53, ectopic expression of
PCL1 confers a proliferative advantage, comparable with
that conferred by PCL2 and PCL3 (Fig. 3C,D). Further-
more, ectopic expression of PCL1, but not PCL2 or
PCL3, in shSCR cells stabilized the protein levels of p53
(Fig. 3B). This increase of p53 protein levels correlated
with increased CDKN1A mRNA and p21 protein levels
(Fig. 3B,E). Additional p53 target genes with established
roles in the negative regulation of cellular proliferation,
includingGADD45A,MDM2, and PAI1, also had elevated
mRNA levels in HDFs ectopically expressing PCL1 but
not PCL2 or PCL3 (Fig. 3E). Furthermore, ChIP analyses
demonstrated that increased transcription of these genes
correlated with increased p53 occupancy at their promot-
ers (Fig. 3F). ChIPs of PCL1 revealed that it was absent
from p53 target gene promoters, suggesting that the
PCL1–p53 interaction takes place “off chromatin.” Inter-
estingly, themRNA levels of a number of p53 target genes
with roles in promoting apoptosis, such as PUMA, BAX,
and NOXA, were not affected by ectopic expression of
PCL1 (Supplemental Fig. S3B), suggesting that PCL1-
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Figure 3. PCL1 is the only PCL that interacts with and stabilizes p53 to block cellular proliferation. (A) Western blot analyses using the
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mediated p53 stabilization leads to context-dependent
downstream transcriptional changes. Taken together,
these data suggest that PCL1 has diverged functionally
from PCL2/3 to mediate its specific negative affects on
cellular proliferation by binding to and stabilizing the
p53 protein off chromatin and in a PRC2-independent
manner.
PCL1 activates p53 target genes and blocks proliferation
independently of chromatin association
We next wished to confirm that the ability of PCL1 to ac-
tivate p53 target genes and negatively affect cellular pro-
liferation is independent of its ability to bind chromatin.
To do this, we took advantage of two conserved residues
within the Tudor domain of the PCL proteins (Fig. 4A),
which we and others demonstrated are required for their
ability to bind chromatin (Ballaré et al. 2012; Brien et al.
2012; Hunkapiller et al. 2012; Musselman et al. 2012;
Cai et al. 2013). We generated mutant forms of each PCL
protein in which these conserved tryptophan and tyrosine
residuesweremutated to cysteine and alanine, respective-
ly. Western blotting of fractionated whole-cell, soluble,
and chromatin-bound lysates confirmed that these Tudor
domain mutations were sufficient to render ectopically
expressed HA-tagged PCL1–3 incapable of binding chro-
matin (Fig. 4B). ChIP analyses confirmed that ectopic ex-
pression of wild-type, but not mutant, PCL1–3 led to the
recruitment of EZH2 and PRC2 activity to the INK4A pro-
moter (Supplemental Fig. S4A). Consistent with this, the
ectopic expression of wild-type, but not mutant, PCL1–3
led to decreases in p16INK4A protein levels (Fig. 4B), which
correlated with decreases in INK4A mRNA levels (Fig.
4C). As expected, the PCL2 and PCL3 Tudor domain mu-
tants did not affect the rate of cellular proliferation, com-
pared with the empty vector control (Fig. 4D). Strikingly,
the removal of the ability of PCL1 to bind chromatin and
repress INK4A led to a pronounced negative effect on
cellular proliferation (Fig. 4D). Interestingly, the ectopic
expression of wild-type and mutant PCL1 led to compara-
ble increases in the levels of several p53 target genes,
including CDKN1A, PAI1, and GADD45A (Fig. 4C; Sup-
plemental Fig. S4B). This suggests that the differential
effect on cellular proliferation between wild-type andmu-
tant PCL1 is due to the ability of wild-type PCL1 to asso-
ciate with chromatin and repress the INK4A gene. Taken
together, these data establish that PCL1 blocks cellular
proliferation by stabilizing p53 independently of INK4A
repression and chromatin association.
Two divergent domains in PCL1 are required
and sufficient for binding p53
Previous work demonstrated that an N-terminal region
encompassing the first PHD domain (PHD1) and a C-ter-
minal region termed “BD2” mediate the ability of PCL1
to bind p53 and block MDM2-mediated ubiquitinylation
of p53 (Yang et al. 2013). A comparison of the amino
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acid sequences of all three PCL proteins revealed that the
PHD1 and BD2 regions of PCL1 have diverged from the
equivalent regions in PCL2 and PCL3 (Fig. 5A). In con-
trast, the Tudor and PHD2 domains of all three proteins
exhibit a broadly conserved sequence identity.
To determine whether the PHD1 and BD2 domains of
PCL1 are sufficient and/or required for its divergent abili-
ty to bind p53, we performed domain swap experiments,
for which we generated six chimeric versions of PCL1
and PCL3 (Fig. 5B). Next, we ectopically expressed these
chimeric proteins and wild-type PCL1 and PCL3 contain-
ing a HA-tag in HDFs.We performed co-IPs using anti-HA
agarose beads and confirmed that all proteins were
capable of associating with EZH2 to a comparable level,
suggesting that they all incorporated into the PRC2 com-
plex (Fig. 5C). Importantly, the PCL1 chimera containing
the PHD1 and BD2 regions of PCL3was incapable of inter-
acting with p53, indicating that these regions are required
for mediating the PCL1–p53 interaction. Conversely, all
three PCL3 chimeras, which contained either one or
both of the PHD1 and BD2 regions of PCL1, were capable
of interacting with p53, indicating that both regions
are sufficient for mediating the interaction. Consistent
with these results, ectopic expression of the PCL1 hybrids
had little or no affect on p53 protein levels or target gene
expression when compared with wild-type PCL1, while
ectopic expression of the PCL3 hybrids led to an increase
in p53 protein levels and CDKN1A mRNA expression
compared with wild-type PCL3 (Fig. 5D,E). Finally,
3T3 growth assays in these cells indicated that the
PCL1–p53 interaction is essential for the ability of PCL1
to negatively affect proliferation, since ectopic expres-
sion of the “PCL3-like” hybrid containing both the
PHD1 and BD2 regions of PCL3, which does not interact
with p53, led to a proliferative advantage in HDFs (Fig.
5F). Moreover, ectopic expression of the equivalent
“PCL1-like” hybrid did not lead to a proliferative advan-
tage despite a reduction in INK4A levels, most likely
owing to increased p53 protein levels and CDKN1A ex-
pression (Fig. 5D–F).
The ability of the PCL1 PHD domain to bind the p53
CTD is a newly evolved function
We next sought to further explore how PCL1 can specifi-
cally interact with p53 and why PCL2 and PCL3 lack
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Figure 5. Two divergent domains within
PCL1 are required and sufficient for its
association with p53 and ability to block
cellular proliferation. (A, top panel) Repre-
sentation of the domain structure of human
PCL1–3. The PHD1 and BD2 regions of
PCL1 were previously shown to interact
with p53. (Bottom panel) Heat map re-
presentations of the level of amino acid
sequence conservation in the indicated
domains of PCL1–3. The bar indicates the
percentage of sequence conservation. (B)
Schematic representation of the PCL1 and
PCL3 domain swap strategy used in this
study. (C ) Western blot analyses using the
indicated antibodies of anti-HA immuno-
precipitations of nuclear protein lysates
prepared from HDFs infected with the indi-
cated pBABE expression constructs. (D)
Western blot analyses using the indicated
antibodies of whole-cell proteins prepared
from cells in C. (E) Quantitative RT–PCR
analyses of the indicatedmRNA transcripts
in cells from C. (F ) 3T3 growth assays per-
formed in cells from C. Assays were initiat-
ed at PD36 and continued for 60 d.
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this ability. To do this, we examined the structural deter-
minants required for the binding specificity of PCL1 ver-
sus PCL2/3. Since predictions indicated that the BD2
region is likely to be largely unstructured (Supplemental
Fig. S5A), we decided to focus our analysis on the PCL1
PHD1 region. This PHD domain shares a 38% sequence
identity with the PHD domain of TRIM24, which has
been cocrystalized with its H3(1–10)K4 substrate peptide
(Tsai et al. 2010). Interestingly, the CTD of p53, which
is the minimal region of p53 required for interaction
with PCL1 (Yang et al. 2013), also bears sequence similar-
ities to H3(1–10). Molecular dynamics simulations of
a homology model of the PCL1 PHD1 based on the
TRIM24 PHD-H3(1–10)K4 complex suggest that two ser-
ine residues (S95 and S106) could be essential for deter-
mining the specificity of PCL1 for p53 (Fig. 6A). In
contrast, PCL2 and PCL3 lack these serines (Fig. 6B). We
next wished to validate the potential importance of these
two serine residues in the PCL1 PHD1 domain for binding
to p53. To do this, we purified recombinant glutathione S-
transferase (GST) fusion protein fragments representing
the PHD1 domains of PCL1–3.Moreover, we also generat-
ed single-pointmutant PCL1 PHD1GST fusions in which
we converted the serine residues to their equivalent resi-
dues in PCL3 (S95G and S106I) in addition to a doublemu-
tant in which both residues were mutated (S95G/S106I).
Next, we performed peptide pull-downs using a biotiny-
lated peptide representing all 30 amino acids of the un-
modified p53 CTD and analyzed these by Western blot
(Fig. 6C). This revealed that the wild-type PHD1 domain
of PCL1 bound the unmodified p53 CTD peptide more
strongly than the same domain in PCL2 and PCL3. Since
these experiments were conducted with an unmodified
p53 CTD peptide, they suggest that PCL1 binding to p53
is not reliant on the presence of specific post-translational
modificationswithin this region. Importantly, the binding
Figure 6. The N-terminal PHD domain of mammalian PCL1 requires two divergent serine residues to associate with the p53 CTD. (A)
Identification of a set of critical residues (hot spots) for the PCL1 PHD1 interactionwith the p53CTD.Ten of the dominant conformations
of PCL1 PHD1 (shown in gray), identified from 2-μsec molecular dynamics (MD) simulations. The PCL1 PHD1 structure had been deter-
mined by homologymodeling based on the TRIM24 PHDdomain in complexwith an unmodified H3(1–10)K4 peptide (ProteinData Bank
[PDB] ID 3o37). The hot spots are labeled by residue type and number, and Zn atoms are shown in cyan. (B) Multiple alignment of the
PHD1 domain of human PCL1, PCl2, and PCL3 proteins, highlighting the divergent serine residues at positions 95 and 106 in PCL1.
(C ) Peptide pull-downs of recombinant GST-tagged PCL1–3 PHD1 domains and mutant PCL1 PHD1 domains, with a biotin-tagged 30-
amino-acid peptide representing the p53 CTD peptide. (D) Representative SPR sensorgrams for the wild-type and mutant PCL1 PHD1
domains binding to the p53 CTD peptide. (E) Segment of alignment of vertebrate PCL proteins showing residues aligned toHomo sapiens
PCL1 Ser95 (first column for each PCL) and Ser106 (second column for each PCL). There is a single PCL in nonvertebrates, as represented
byDrosophila. The phylogenetic tree indicates the species relationships; branch lengths are not to scale. Where there was more than one
representative of a group and where they did not have identical sequences, the ancestral residue was inferred as the one requiring the few-
est evolutionary changes. Such cases are indicated with an asterisk.
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of the PCL1 containing point mutations in the PHD1
domain to the p53CTDpeptidewas impaired, directly im-
plicating these residues as essential mediators of the
PCL1–p53 interaction. Next, we performed surface plas-
mon resonance (SPR) to accurately measure the in vitro
binding of the recombinant GST proteins to the p53
CTD peptide (Fig. 6D). This validated the peptide pull-
down analysis, confirming that both serines are required
for the in vitro interaction between GST-PCL1 PHD1
and the p53 CTD peptide (Fig. 6D; Supplemental Fig.
S5B). It also revealed that the binding of GST-PCL1-
PHD1 to the p53 CTD peptide was highly reproducible,
with an apparent Kd of 26.4 nM, as determined from inde-
pendentmeasurements at four different concentrations of
the protein (Supplemental Fig. S5C; data not shown). Tak-
en together, these data revealed that the two serine resi-
dues at positions 95 and 106 of the N-terminal PHD
domain of PCL1, which have diverged from PCL2/3, are
necessary for the specific, high-affinity binding of PCL1
to the p53 CTD.
In order to understand the evolutionary origins of the
two PCL1 serine residues, we performed a multiple se-
quence alignment and evolutionary tree analysis of the
vertebrate PCL proteins (Fig. 6E). This confirmed that
the three PCL genes are present in all vertebrates and
are related through two whole-genome duplications at
the base of the vertebrate tree (Makino and McLysaght
2010). Wewere specifically interested in whether the abil-
ity to bind p53 is a newly evolved function of PCL1 (that
is, a so-called “neofunctionalization” event) or an ances-
tral function that was lost from the other two PCLs. The
pattern of sequence divergence at sites corresponding to
human Ser95 and Ser106 clearly indicates that the substi-
tutions giving rise to each of these residues occurred
uniquely in PCL1 after the duplication events. Important-
ly, these two serine residues are completely conserved
across all mammalian PCL1 genes and, furthermore,
uniquely co-occur in mammals (Fig. 6E). This suggests
that PCL1 has undergone neofunctionalization during
evolution, acquiring the ability to bind the p53 CTD in
mammals.
Endogenous PCL1 stabilizes p53 to underpin cellular
quiescence
Wenext wished to further explore the potential biological
significance of the PCL1–p53 interaction. Interestingly,
despite the dramatic increase in p53 protein levels in qui-
escent cells, MDM2 mRNA and protein levels are un-
changed between proliferating and nonproliferating
cells (Supplemental Fig. S6A,B). This observation, taken
together with the work of Yang et al. (2013), who demon-
strated that PCL1 blocks MDM2-mediated ubiquitinyla-
tion of p53, suggested that the changes in PCL1 protein
levels between quiescent and growing cells may be key
to stabilizing p53 in these cells, thereby maintaining cells
in a nonproliferative state. To test this possibility, we
evaluated the functional consequences of transiently
knocking down PCL1, TP53, or PCL3 (as a negative con-
trol) in serum-starved quiescent HDFs (Fig. 7A). The
depletion of PCL1 led to a decrease in the levels of p53 pro-
tein and CDKN1A mRNA (Fig. 7A,B). In contrast, the
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Figure 7. PCL1 stabilizes p53 to maintain cel-
lular quiescence. (A) Western blot analyses us-
ing the indicated antibodies on whole-cell
protein lysates from HDF cells transfected
with siRNAs targeting TP53, PCL1, or PCL3
and then placed in serum-freemedium for a fur-
ther 72 h. (B) Quantitative RT–PCR analyses of
the indicated mRNA transcripts on cells from
C. (C ) Representative data from a multicolor
flow cytometry experiment used to determine
the percentage of quiescent cells in serum-
starved HDFs from C. Quiescent cells are de-
fined as having low levels of Pyronin Y (RNA)
and DRAQ5 positivity (DNA). (D) Quantifica-
tion of the percentage of serum-starved HDFs
in quiescence in cells from C. n = 6.
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depletion of PCL3 had no affect on p53 protein levels or
CDKN1A expression, further supporting the idea that
PCL1 plays a specific role in stabilizing p53.
Since the p53 protein plays an essential role in main-
taining cellular quiescence (Itahana et al. 2002; Meletis
et al. 2006; Liu et al. 2009; Cheung and Rando 2013), we
next asked whether depletion of PCL1 would phenocopy
loss of p53 in our in vitro model of cellular quiescence.
To do this, we quantified the proportion of quiescent cells
following siRNA-mediated depletion of TP53, PCL1, and
PCL3 in serum-starved quiescent HDFs (Fig. 7C,D). Re-
markably, this demonstrated that depletion of PCL1 led
to a similar, approximately twofold reduction in the over-
all quiescent population, similar to p53 depletion in these
cultures, whereas depletion of PCL3 had no effect (Fig. 7C,
D). These effects on quiescence maintenance are compa-
rable with previous in vivo results, where p53 knockout
in quiescent HSCs results in a 1.5-fold to twofold reduc-
tion in quiescent HSCs (Liu et al. 2009). This is particular-
ly remarkable because these cells do not have serum or
growth factors that would normally be required for quies-
cent cells to exit the G0 block and enter the cell cycle.
Taken together, these data indicate that PCL1 specifically
stabilizes the p53 protein in quiescent cells and, like p53,
is required for themaintenance of the quiescent cell state.
Discussion
Our initial observation that, unlikePCL2 and PCL3, PCL1
is expressed in quiescent cells suggested that it might
have a unique function in nondividing cells. We pursued
this and unraveled an essential PCL1–p53 regulatory
axis. The PCL1 gene is transcriptionally regulated by
p53 in quiescent cells, while the PCL1 protein physically
interacts with the p53 protein to stabilize it. Remarkably,
mammalian PCL1 has only recently evolved the ability to
bind the p53 CTD through the acquisition of two unique
serine residues in its N-terminal PHD domain. We show
here that this divergent ability of PCL1 is both PRC2-
and chromatin-independent and is essential in quiescent
cells to maintain their nonproliferative state.
PCL1 as an upstream regulator of cellular quiescence
Our initial demonstration that the PCL1 gene is highly ex-
pressed in quiescent cells prompted us to investigate its
potential role as a regulator of cellular quiescence. We ob-
served that ectopic expression of PCL1 was sufficient to
mediate stabilization of p53 protein levels, leading to in-
creased transactivation of p53 target genes such as
CDKN1A and ultimately to an accumulation of G0/quies-
cent cells. Moreover, transient loss of PCL1was sufficient
to phenocopy p53 depletion in an in vitromodel of cellular
quiescence. This is a particularly interesting finding, since
no Polycomb group protein has previously been linked
with a direct role in the regulation of cellular quiescence,
and raises the possibility that, like p53, PCL1 could be re-
quired to maintain the quiescent state of tissue-specific
stem cells in vivo (Itahana et al. 2002; Meletis et al.
2006; Liu et al. 2009; Cheung and Rando 2013). This pos-
sibility will require additional study and the generation of
suitable in vivo geneticmodels for the study of PCL1 func-
tion in the context of cellular quiescence. A challenge
here will be the fact that a straightforward conditional
deletion of Pcl1 in quiescent stem cells would likely
also disrupt its other function within the PRC2 complex.
In this regard, it is worth noting that loss of PRC2 compo-
nents such as Ezh1 or Eed in HSCs leads to the aberrant
activation of Polycomb target genes, including Ink4a,
and consequent downstream phenotypic changes (Hidal-
go et al. 2012; Xie et al. 2014). Therefore, to delineate
the two functions of PCL1, it will be necessary to generate
a conditional PCL1 allele, producing a protein incapable of
interacting with p53 but still capable of recruiting and
maintaining the PRC2 complex to target genes. There-
fore, a more extensive molecular characterization of the
PCL1–p53 interaction will be necessary to guide the gen-
eration of such an allele and thereby help further decipher
the molecular mechanisms regulating adult stem cell
quiescence.
PCL1 as a new example of neofunctionalization
We provide evidence that the PCL1 gene has undergone
neofunctionalization, acquiring the unique ability among
the three PCL proteins to bind the CTD of p53. However,
we also show that the PCL1 protein retains its ancestral
function within the PRC2 complex. The divergent N-ter-
minal PHD domain andC-terminal “BD2” region of PCL1
are both required and sufficient for this unique ability.We
further characterized two unique serines in the N-termi-
nal PHD domain of PCL1 that have emerged during verte-
brate evolution and are essential for its interaction with
p53. This functional divergence of PCL1 goes some way
to explaining the acquisition and ultimate maintenance
of multiple PCL genes in vertebrate genomes. They are
not redundant copies, as might have seemed to be the
case, but have a novel functionality that evolved alongside
the ancestral one. The idea of neofunctionalization of
duplicated genes has been popular for >40 years (Ohno
1970), but there are relatively few examples such as this,
where the sequence substitutions involved have been
clearly described (Conant and Wolfe 2008). Therefore,
PCL1 represents an archetypal example of neofunctional-
ization, and further studies into its functional interplay
with p53 will likely shed new light on the evolution of
the molecular mechanisms regulating the process of cel-
lular quiescence.
Roles of PCL proteins in cancer
Our results have implications for how the deregulation of
PCL protein function could contribute to cancer. We
show that ectopic expression of PCL1–3 leads to an in-
crease in the recruitment of the PRC2 complex and
H3K27me3 deposition on the INK4A tumor suppressor
gene locus. Therefore, the elevated levels of PCL3 ob-
served in multiple cancer types (Wang et al. 2004; Li
et al. 2013) could directly contribute to their sustained
proliferation by increasing the function of the PRC2
Brien et al.
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complex on Polycomb target genes such as INK4A. It is in-
teresting to note that no other PRC2 component has been
reported to repress INK4A when ectopically expressed,
despite their requirement to maintain its repression
(Bracken et al. 2007). This is likely related to the stoichi-
ometry of the PRC2 complex and the fact that the core
components—EZH1/2, SUZ12, and EED—exist at a ratio
of 1:1:1 in vivo (Smits et al. 2013), which is essential for its
activity (Kuzmichev et al. 2002), making it unlikely that
overexpression of a single core PRC2 component would
lead to increased PRC2 activity. However, since the
PCL1–3 proteins exist in less than one in five PRC2 com-
plexes (Smits et al. 2013), it follows that overexpression of
any one PCL protein would stabilize the binding of PRC2
on its target genes. Furthermore, since PCL proteins re-
quire their Tudor domain to associate with chromatin,
targeting this domain could be a novel therapeutic strat-
egy to reactivate INK4A in cancer cells, particularly in
cancers with deregulated PRC2 function.
The PCL1 gene is frequently translocated in endometri-
al stromal sarcomas, and the PCL1 fusion products have
been proposed to contribute directly to the pathogenesis
of these cancers (Micci et al. 2006; Sauvageau and Sauva-
geau 2010). However, the mechanisms of how PCL1 fu-
sion gene products could contribute to oncogenesis are
unexplored. Interestingly, while these PCL1 fusion genes
retain the vast majority of the PCL1-coding sequence, the
promoter region is lost in the translocation event, imply-
ing that the normal transcriptional control of PCL1 is lost
in the case of the fusion genes. Therefore, we speculate
that ectopic expression of these PCL1 fusions may con-
tribute to cancer by increasing PRC2 complex function,
potentially leading to the repression of Polycomb target
genes such as INK4A. Intriguingly, our study and the na-
ture of the PCL1 fusion genes would suggest that the
PCL1 fusion gene products should retain the ability of
wild-type PCL1 to interact with p53, raising questions
about the status of theTP53 gene in these cancers. Finally,
strategies to block the PCL1–p53 interaction could poten-
tially be exploited for therapeutic gain in cancer. For ex-
ample, it will be important to examine the relationship
of PCL1 and wild-type p53 in quiescent, slowly proliferat-
ing cancer stem cells in vivo, since disrupting the interac-
tion could force these cells into the cell cycle, potentially
rendering them more sensitive to chemotherapy.
In conclusion, our study not only establishes criti-
cal functions for PCL1–3 in positively and negatively reg-
ulating cellular proliferation but also highlights potential
opportunities to exploit this knowledge for cancer
therapy.
Materials and methods
Cell culture and RNAi
HDFs and viral packaging cells were grown in DMEM (Gibco)
with 10% (v/v) FBS (Gibco), 100 U/mL penicillin, and 100 U/
mL streptomycin (Gibco). For serum starvation experiments, se-
rum was removed for 96 h, and cells were stimulated to re-enter
the cell cycle by addition of medium containing 20% (v/v) FBS
for 24 h. For RNAi experiments, HDFs were transfected at
30%–50% confluence with 20 μM siRNA using Lipofectamine
RNAi MAX (Invitrogen).
3T3 growth assays and cell cycle analyses
For 3T3 assays, 7.5 × 105 cells were plated on 100-mm plates.
Three days later, the total number of cells was counted, and
7.5 × 105 cells were plated again. The cumulative increase in
cell number was calculated according to the formula log(Nf/
Ni)/log2,whereNi andNf are the initial and final numbers of cells
plated and counted after 3 d, respectively. For BrdU FACS analy-
ses, cells were pulsed with 33 μMBrdU for 45 min. BrdU incorpo-
ration was measured using an anti-BrdU antibody followed by
FACS analysis. DNA content was measured by propidium iodide
staining. For G0, FACS cells were stained with 10 μM DRAQ5
(Biostatus) and 5 μg/mL Pyronin Y at 37°C.
Immunoprecipitations
Immunoprecipitations were performed as previously described
(Van Den Berg et al. 2010). Briefly, nuclear pellets were lysed in
buffer C containing protease inhibitors (20 mM HEPES at pH
7.6, 20% [v/v] glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM
EDTA, aprotinin 1 μg mL−1, leupeptin 10 μg mL−1, PMSF 1
mM) and subsequently dialyzed against buffer C-100 (20 mM
HEPES at pH 7.6, 20% [v/v] glycerol, 0.2 mM EDTA, 100 mM
KCl, 1.5 mM MgCl2, 0.2 mM EDTA). Antibody-coupled beads
were incubated with dialyzed nuclear extracts containing 250 U
of benzonase (Sigma) for 3 h at 4°C. Beads were then washed,
and elutions were performed with 2× SDS loading dye or 250
μg/mL HA peptide (Sigma).
ChIP
ChIP analyses were performed as described (Brien et al. 2012).
Briefly, formaldehyde cross-linked chromatin was sheared to
200–1000 base pairs by sonication. Chromatin was incubated
overnight at 4°Cwith the indicated antibodies, and immune com-
plexes were extracted using protein A or G Sepharose beads
(Sigma). ChIP sampleswere eluted, andDNAwas purified by phe-
nol/chloroform extraction and ethanol precipitation.
Quantitative real-time PCRs
Total RNA was extracted from cells using the RNeasy kit (Qia-
gen) and was used to generate cDNA by RT–PCR using the Taq-
Man reverse transcription kit (Applied Biosystems). Relative
mRNA expression levels were determined using the SYBRGreen
I detection chemistry (Applied Biosystems).
Purification of recombinant GST fusion proteins
The PCL1/2/3-PHD1 fragments were cloned into pGEX-6P1 and
expressed in BL21-DE3 Escherichia coli. Protein expression was
induced by addition of 0.5 mM IPTG to bacteria cultures, and
GST fusion proteins were purified over GSH-agarose beads
(Pierce).
In vitro peptide pull-down
Biotinylatedp53CTDpeptide (residues363–393), boundto strepa-
vidin-coated agarose beads (Invitrogen), was incubated for 30min
withGST fusion proteins. Beadswerewashed extensively in bind-
ing buffer, and bound protein was eluted using 2× Laemlli dye.
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SPR
Biotinylated p53 C-terminal peptide was immobilized on a strep-
tavidin-coated SPR surface, and concentration series of each
GST-PCL-PHD1 fusion proteins were subsequently injected to
determine interaction affinities (Kd).
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